IL10RA and uveal melanoma: On the other hand, cancer immunization with simultaneous IL-10 signaling blockade, using IL-10R monoclonal antibodies, soluble IL-10R, peptide-based IL-10R antagonists, or oligonucleotides, raised tumor immune response with evidence of clinical benefits in different advanced solid tumors, such as renal cell carcinoma and uveal melanoma (112, 191, 197, 198), and enhances CD8+ T cell response and potentiates vaccine-induced tumor regression (189).